BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//European Brain Council (EBC) - ECPv6.15.19//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:European Brain Council (EBC)
X-ORIGINAL-URL:https://www.braincouncil.eu
X-WR-CALDESC:Events for European Brain Council (EBC)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20210608T130000
DTEND;TZID=UTC:20210608T173000
DTSTAMP:20260415T201934
CREATED:20210318T192745Z
LAST-MODIFIED:20211026T090546Z
UID:28316-1623157200-1623173400@www.braincouncil.eu
SUMMARY:Value of Treatment 2 Synthesis Meeting
DESCRIPTION:  \nThe European Brain Council (EBC) is pleased to invite you for the Value of Treatment 2 (VOT 2) Synthesis Meeting\, to be held virtually on 8 June 2021 (13:00-17:00 CET). Experts participating in the research will present a synthesis of the results so far and examine the most critical issues in brain diseases in Europe from different perspectives including policymakers\, innovators\, academia and industry\, medical professionals and patient organisations. \n  \nStudy background\nValue of Treatment (VOT) for brain disorders\nThe Value of Treatment (VOT) for brain disorders is a health economics and outcomes research project addressing all brain disorders and coordinated by EBC. Brain disorders – both neurological and mental alike – constitute a major factor\, alongside cancers and cardiovascular diseases\, driving the overall burden of diseases in Europe. Neurological and psychiatric disorders across all lifespans are the leading cause of poor health and disability in Europe. The conclusions of the VOT research project first round released in 2017 (which included case studies on disorders ranging from schizophrenia to Alzheimer’s disease\, epilepsy\, headache\, normal pressure hydrocephalus\, Parkinson’s disease\, multiple sclerosis\, restless legs syndrome and stroke) highlighted the need for more research\, early\, if possible prodromal\, diagnosis and intervention\, integrated seamless care underpinning timely care pathways as a solution to address value-based health care in Europe and access to the best treatments available.   \nValue of Treatment (VOT 2): a second round of case studies\nIn the continuity of these conclusions and in the framework of the VOT research\, a second round of case studies (VOT2) have been developed on new therapeutic areas focusing on rare diseases (Ataxia\, Dystonia and Phenylketonuria) and mental disorders (Anorexia Nervosa\, Autism Spectrum Disorder\, Major Depressive Disorder). The study to be finalised in 2021 is focusing on “early intervention\, bridging the gaps and achieving seamless\, coordinated care”\, and the objective is to examine health gains resulting from optimized healthcare interventions in comparison with current care or no treatment\, and converge data evidence to policy recommendations on how to improve the care pathway(s). Previous joint working sessions aimed to exchange and build synergy between the research-work and DG Sante Rare diseases European Reference Networks (ERNs) programme and research as well as the PECUNIA project from the EU Framework on mental health and well-being. Beyond the research design and considering current context\, the impact of COVID-19 on treatment and healthcare transformation is also explored.  \n  \nClick here to view the programme \nDownload the event report \n  \nPlease see below the final agenda: \nAGENDA VOT2 SYNTHESIS MEETING 8 June 2021 - FINAL
URL:https://www.braincouncil.eu/event/value-of-treatment-2-synthesis-meeting/
END:VEVENT
END:VCALENDAR